Oxford BioDynamics Demonstrates Ability To Predict Progression Of ALS

LONDON (Alliance News) - Biotechnology company Oxford Biodynamics PLC said on Wednesday ...

Alliance News 11 October, 2017 | 12:20PM
Email Form

LONDON (Alliance News) - Biotechnology company Oxford Biodynamics PLC said on Wednesday presented two distinct epigenetic signatures for both an amyotrophic lateral sclerosis diagnosis and prognosis at the Northeast ALS Consortium meeting in Florida.

The prospective study's objective was to determine the sensitivity and specificity of two signatures for the diagnosis of ALS and prognosis of its progression. 100 patients' samples were compared to control at three to six months following the initial clinical visit. During the visit, those taking part undertook the ALS-functional rating scale-revised assessment, forced vital capacity tests and used EpiSwitch to analyse blood samples.

Interrogation of the genomic architecture from healthy and diseased blood samples identified two unique epigenetic signatures: One with diagnostic potential and the other for prognostic predictions. The diagnostic signature had specificity and sensitivity of 75% and 88%, while the prognostic test had sensitivity and specificity of 80%.

"We are delighted to present two distinct epigenetic signatures for ALS diagnosis and prognosis at the annual NEALS meeting in Florida. This prospective study has delivered two new and unique epigenetic biomarker signatures that have the potential to improve the time to diagnosis and provide a predictive prognosis for the progression of the disease. We look forward to further expanding our EpiSwitch ALS studies in close collaboration with leading clinical experts, both in US and UK. Our aim is to contribute to improvement in ALS patient care and to support ALS therapeutic developments by improving diagnostic and prognostic patient stratifications," said Chief Scientific Officer Alexandre Akoulitchev.

Shares in Oxford BioDynamics were down 1.0% at 240.01 pence on Wednesday.

By Dayo Laniyan; dayolaniyan@alliancenews.com

Copyright 2017 Alliance News Limited. All Rights Reserved.

Email Form

Securities Mentioned in Article

Security Name Price Change (%) Morningstar
Oxford BioDynamics PLC 60.75 GBX 2.10 -

About Author

Alliance News

Alliance News provides Morningstar with continuously updating coverage of news affecting listed companies.

Audience Confirmation

By clicking 'accept' I acknowledge that this website uses cookies and other technologies to tailor my experience and understand how I and other visitors use our site. See 'Cookie Consent' for more detail.

  • Other Morningstar Websites
© Copyright 2020 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Cookies